Literature DB >> 11797021

Outcome of mechanical ventilation for acute respiratory failure in patients with pulmonary fibrosis.

T Fumeaux1, C Rothmeier, P Jolliet.   

Abstract

OBJECTIVE: During the course of idiopathic pulmonary fibrosis patients may need invasive mechanical ventilation because of acute respiratory failure. We reviewed the charts of all patients with idiopathic pulmonary fibrosis admitted to our ICU for mechanical ventilation to describe their ICU course and prognosis. DESIGN AND
SETTING: Retrospective, observational case series, from December 1996 to March 2001, in an 18-bed medical ICU in a tertiary university hospital. PATIENTS: Fourteen consecutive patients with idiopathic ( n=11) or secondary ( n=3) pulmonary fibrosis admitted to the medical ICU for mechanical ventilation. MEASUREMENTS AND
RESULTS: Relevant factors of history and hospital course such as diagnostic and therapeutic interventions were retrieved as well as laboratory and radiological results. All patients were admitted for severe acute hypoxemic respiratory failure (PaO(2)/FIO(2) 111+/-64 mmHg), with a high clinical suspicion of lower respiratory tract infection. Despite ventilatory support and adjunctive therapies (antibiotics, steroids, or immunosuppressive drugs), all patients gradually worsened and eventually died in the ICU after a mean stay of 7.6+/-4.6 days.
CONCLUSIONS: In this study mechanical ventilation for acute respiratory failure in pulmonary fibrosis patients was associated with a 100% mortality, despite aggressive therapeutic and diagnostic procedures.

Entities:  

Mesh:

Year:  2001        PMID: 11797021     DOI: 10.1007/s00134-001-1150-0

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  23 in total

1.  Ventilator settings and outcome of respiratory failure in chronic interstitial lung disease.

Authors:  Evans R Fernández-Pérez; Murat Yilmaz; Hussam Jenad; Craig E Daniels; Jay H Ryu; Rolf D Hubmayr; Ognjen Gajic
Journal:  Chest       Date:  2007-11-07       Impact factor: 9.410

2.  An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.

Authors:  Ganesh Raghu; Harold R Collard; Jim J Egan; Fernando J Martinez; Juergen Behr; Kevin K Brown; Thomas V Colby; Jean-François Cordier; Kevin R Flaherty; Joseph A Lasky; David A Lynch; Jay H Ryu; Jeffrey J Swigris; Athol U Wells; Julio Ancochea; Demosthenes Bouros; Carlos Carvalho; Ulrich Costabel; Masahito Ebina; David M Hansell; Takeshi Johkoh; Dong Soon Kim; Talmadge E King; Yasuhiro Kondoh; Jeffrey Myers; Nestor L Müller; Andrew G Nicholson; Luca Richeldi; Moisés Selman; Rosalind F Dudden; Barbara S Griss; Shandra L Protzko; Holger J Schünemann
Journal:  Am J Respir Crit Care Med       Date:  2011-03-15       Impact factor: 21.405

3.  Risk of acute exacerbation of interstitial pneumonia after pulmonary resection for lung cancer in patients with idiopathic pulmonary fibrosis based on preoperative high-resolution computed tomography.

Authors:  Hidemi Suzuki; Yasuo Sekine; Shigetoshi Yoshida; Makoto Suzuki; Kiyoshi Shibuya; Yoko Yonemori; Kenzo Hiroshima; Yukio Nakatani; Satoko Mizuno; Yuichi Takiguchi; Ichiro Yoshino
Journal:  Surg Today       Date:  2011-07-12       Impact factor: 2.549

Review 4.  Acute exacerbation of idiopathic pulmonary fibrosis-a review of current and novel pharmacotherapies.

Authors:  Maya M Juarez; Andrew L Chan; Andrew G Norris; Brian M Morrissey; Timothy E Albertson
Journal:  J Thorac Dis       Date:  2015-03       Impact factor: 2.895

5.  Outcomes and Mortality Prediction Model of Critically Ill Adults With Acute Respiratory Failure and Interstitial Lung Disease.

Authors:  Whitney D Gannon; David J Lederer; Mauer Biscotti; Azka Javaid; Nina M Patel; Daniel Brodie; Matthew Bacchetta; Matthew R Baldwin
Journal:  Chest       Date:  2018-01-17       Impact factor: 9.410

Review 6.  Biofabrication of phenotypic pulmonary fibrosis assays.

Authors:  Cameron Yamanishi; Stephen Robinson; Shuichi Takayama
Journal:  Biofabrication       Date:  2019-06-19       Impact factor: 9.954

Review 7.  [Chronic critically ill patients from a pneumological perspective].

Authors:  M Pfeifer
Journal:  Med Klin Intensivmed Notfmed       Date:  2013-04-12       Impact factor: 0.840

Review 8.  Clinical review: idiopathic pulmonary fibrosis acute exacerbations--unravelling Ariadne's thread.

Authors:  Spyros A Papiris; Effrosyni D Manali; Likurgos Kolilekas; Konstantinos Kagouridis; Christina Triantafillidou; Iraklis Tsangaris; Charis Roussos
Journal:  Crit Care       Date:  2010-12-22       Impact factor: 9.097

9.  Suppression of expression of heat shock protein 70 by gefitinib and its contribution to pulmonary fibrosis.

Authors:  Takushi Namba; Ken-ichiro Tanaka; Tatsuya Hoshino; Arata Azuma; Tohru Mizushima
Journal:  PLoS One       Date:  2011-11-09       Impact factor: 3.240

10.  Outcomes for hospitalized patients with idiopathic pulmonary fibrosis treated with antifibrotic medications.

Authors:  Bryan T Kelly; Viengneesee Thao; Timothy M Dempsey; Lindsey R Sangaralingham; Stephanie R Payne; Taylor T Teague; Teng Moua; Nilay D Shah; Andrew H Limper
Journal:  BMC Pulm Med       Date:  2021-07-17       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.